Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Artigo
Inglês
| MEDLINE | ID: mdl-36511784
2.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Blood
; 2024 May 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38713888
3.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood
; 140(8): 839-850, 2022 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-35605176
4.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38088119
5.
Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
Int J Mol Sci
; 25(3)2024 Jan 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38338868
6.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(12): 1423-1433, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37944541
7.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(2): 139-150, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36642080
8.
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Future Oncol
; 2023 01 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36617990
9.
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
Int J Mol Sci
; 24(3)2023 Feb 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36769265
10.
An elevated systemic inflammation index is related to an inferior response to pomalidomide and dexamethasone treatment in patients with relapsed and refractory multiple myeloma.
Contemp Oncol (Pozn)
; 27(3): 139-146, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38239862
11.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35810754
12.
New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
Curr Treat Options Oncol
; 23(6): 775-795, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35357653
13.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 378(12): 1107-1120, 2018 Mar 22.
Artigo
Inglês
| MEDLINE | ID: mdl-29562156
14.
Hairy cell leukemia: a brief update on current knowledge and treatment prospects.
Curr Opin Oncol
; 33(5): 412-419, 2021 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34264896
15.
Skin changes in hairy cell leukemia.
Ann Hematol
; 100(3): 615-625, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33216198
16.
Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
Acta Haematol
; 144(4): 365-379, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33238270
17.
The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications.
Int J Mol Sci
; 22(21)2021 Nov 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34769503
18.
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
Br J Haematol
; 190(5): 736-740, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32236950
19.
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.
Blood
; 132(9): 892-902, 2018 08 30.
Artigo
Inglês
| MEDLINE | ID: mdl-29997221
20.
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
Blood
; 131(21): 2331-2334, 2018 05 24.
Artigo
Inglês
| MEDLINE | ID: mdl-29487070